 |
More: Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management Hepatitis B: Advances in Screening, Diagnosis, and Clinical Management -- Volume 2 CME Author Information and Disclosures Release Date: May 29, 2008; Valid for credit through May 29, 2009 | Physicians - maximum of 1.5 AMA PRA Category 1 Credit(s)™ for physicians | | To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details. Contents of This CME Activity- Understanding Resistance in Hepatitis B -- Clinical ImplicationsPreventing HBV antiviral drug resistance to the oral antivirals and appropriate management when resistance occurs is crucial in the treatment of hepatitis B. Drs. Reddy and Martin review the issues.Chakradhar M. Reddy, MD; Paul Martin, MD, FACP (Expert Column, May 29, 2008)
- Advances in Hepatitis B: An Update From EASL 2008Nancy Reau, MD, reviews the latest information regarding hepatitis B, as framed by new data presented at EASL 2008.Nancy S. Reau, MD (Conference Report, May 29, 2008)
- Strategies in the Management of Chronic Hepatitis BTarek Hassanein, MD, FACP, FACG, and Deanna Oliver, BS, address issues in the treatment of chronic hepatitis B, with a view toward the management of antiviral drug resistance.Deanna L. Oliver, BS; Tarek Hassanein, MD, FACP, FACG (Case Report, May 29, 2008)
Legal DisclaimerThe material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © 2008 Medscape. |
|
|
Learning Objectives Upon completion of this activity, participants will be able to: - Summarize the development of HBV drug resistance with the oral antiviral agents and describe strategies to monitor/manage drug resistance in chronic HBV infection
- Review current and emerging concepts and strategies in the management of
patients infected with the hepatitis B virus, as based on new data presented at EASL 2008
- Discuss the approach to managing the patient with lamivudine-resistant hepatitis B, including when to stop therapy and when to switch therapy
Authors and Disclosures Paul Martin, MD, FACP
Disclosure: Paul Martin, MD, FACP, has
disclosed that he has received grants for clinical research and educational activities from, and has served as an advisor or consultant to, Bristol-Myers Squibb, Gilead, Idenix, and Novartis. Chakradhar M. Reddy, MD
Disclosure: Chakradhar M. Reddy, MD, has disclosed no relevant financial relationships. Nancy S. Reau, MD
Disclosure: Nancy S. Reau, MD, has
disclosed that she has received grants for clinical research from, and served as an advisor or consultant to, Gilead. Dr. Reau has also disclosed that she has served as an advisor or consultant to Bristol-Myers Squibb. Tarek Hassanein, MD, FACP, FACG
Disclosure: Tarek Hassanein, MD, FACP, FACG, has disclosed that he has received grants for clinical research from Bristol-Myers Squibb, GlaxoSmithKline, Roche, and Vertex
Pharmaceuticals Inc. Dr. Hassanein has also disclosed that he has served on the speaker's bureau for Bristol-Myers Squibb, Novartis, Roche, and Three Rivers Pharmaceuticals. He has also disclosed that he has served on the advisory board of Gilead and Roche. Deanna L. Oliver, BS
Disclosure: Deanna L. Oliver, BS, has disclosed no relevant financial relationships. Maria
Gaiso
Disclosure: Maria Gaiso has disclosed no relevant financial relationships. |
 |
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Medscape, LLC designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Contact This Provider
|
|
